T80.310S ABO incompatibility with acute hemolytic transfusion reaction, sequela

Name of the Condition

• ABO incompatibility with acute hemolytic transfusion reaction, sequela.

Summary

This condition describes the residual effects or chronic complications that persist after an acute hemolytic transfusion reaction due to ABO incompatibility. It represents the long-term consequences of the initial immune-mediated destruction of red blood cells, which can lead to ongoing organ damage or functional impairment. The term "sequela" indicates that the condition is a late effect of the acute event, rather than an active, ongoing reaction.

Causes

ABO incompatibility reactions result from the transfusion of blood or blood products containing ABO antigens that do not match the recipient's blood type. The initial acute reaction is driven by pre-existing antibodies in the recipient that target donor red blood cells, causing hemolysis. Sequelae arise from the damage sustained during this acute phase, such as kidney injury, liver dysfunction, or chronic anemia, which may persist or develop after the acute event has resolved.

Risk Factors

• Prior acute hemolytic transfusion reaction due to ABO incompatibility
• Delayed or inadequate treatment of the initial reaction
• Underlying comorbidities (e.g., pre-existing kidney disease) that increase susceptibility to long-term damage
• Repeated exposure to incompatible blood products in subsequent transfusions

Symptoms

• Persistent fatigue or weakness
• Chronic kidney dysfunction (e.g., elevated creatinine, reduced urine output)
• Jaundice or persistent anemia
• Unexplained organ dysfunction (e.g., liver, heart) without acute triggers

Diagnosis

Diagnosis of sequelae requires correlation with a prior documented acute hemolytic transfusion reaction and evidence of ongoing or residual damage. Clinical evaluation focuses on identifying persistent symptoms or organ dysfunction, supported by laboratory tests (e.g., hemoglobin levels, renal function panels) or imaging. A history of the initial transfusion event and its acute presentation is critical for confirming the link to the sequela.

Treatment Options

Management is tailored to the specific residual effects, such as treating chronic anemia with iron supplementation or addressing kidney dysfunction with nephroprotective measures. Supportive care, including monitoring for worsening organ function, is essential. In some cases, long-term therapies (e.g., dialysis for renal failure) may be required, depending on the severity of the sequelae.

Prognosis and Follow-Up

Prognosis varies based on the extent of organ damage and the timeliness of initial treatment. Mild sequelae may resolve with supportive care, while severe cases (e.g., end-stage renal disease) may have lasting impacts. Regular follow-up is necessary to monitor organ function and adjust treatment as needed. Long-term outcomes depend on the resilience of the affected systems and the effectiveness of management.

Complications

• Chronic kidney disease or failure
• Persistent anemia requiring ongoing intervention
• Liver dysfunction or failure
• Cardiovascular complications (e.g., hypertension from renal impairment)
• Increased risk of future transfusion reactions if ABO compatibility is not strictly maintained

Lifestyle & Prevention

Prevention of sequelae hinges on avoiding future ABO-incompatible transfusions through rigorous blood typing, crossmatching, and verification protocols. Patients with a history of such reactions should carry medical alerts (e.g., blood type cards) and inform healthcare providers of their transfusion history. Lifestyle modifications, such as managing comorbidities (e.g., diabetes, hypertension), may help mitigate organ damage.

When to Seek Professional Help

Seek immediate medical attention for new or worsening symptoms, such as severe fatigue, jaundice, reduced urine output, or signs of organ failure (e.g., confusion, swelling). Regular follow-up with a healthcare provider is recommended to monitor for delayed complications, especially if prior organ damage was significant.

Tips for Medical Coders

Code T80.310S is used for sequelae of an ABO incompatibility with acute hemolytic transfusion reaction. Document the link to the prior acute event and the specific residual effects (e.g., chronic kidney disease) to support coding. Ensure the diagnosis reflects the long-term nature of the condition, not an active acute reaction. Verify that the sequela is directly attributable to the initial transfusion incident.